• +1-646-491-9876
    • +91-20-67278686

    Search

    Pituitary ACTH Hypersecretion Pipeline Review H1 2017

    Pituitary ACTH Hypersecretion Pipeline Review H1 2017

    • Report Code ID: RW0001858646
    • Category Pharmaceuticals
    • No. of Pages 56
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2017, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline landscape.

    Cushing disease is a condition in which the pituitary gland releases too much adrenocorticotropic hormone (ACTH) . Symptoms include acne or skin infections, backache, mental changes, such as depression, anxiety, or changes in behavior. Treatment includes surgery and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 2, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Pituitary ACTH Hypersecretion (Cushing Disease) - Overview
    Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development
    Amryt Pharma plc
    Crinetics Pharmaceuticals Inc
    Cyclacel Pharmaceuticals Inc
    Ipsen SA
    Millendo Therapeutics Inc
    Novartis AG
    Pfizer Inc
    Strongbridge Biopharma plc
    Pituitary ACTH Hypersecretion (Cushing Disease) - Drug Profiles
    Antisense RNAi Oligonucleotide to Inhibit Pro-Opiomelanocortin for ATCH-Dependent Cushing's syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AP-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ATR-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BIM-23B065 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    levoketoconazole - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MPP-482 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    osilodrostat phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pasireotide ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    seliciclib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Cushing Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize Melanocortin Receptor 2 for ACTH-dependent Cushing's syndrome and Congenital Adrenal Hyperplasia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    veldoreotide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects
    Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products
    Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones
    Featured News & Press Releases
    Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
    Feb 23, 2015: Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare Diseases
    Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo
    Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014
    Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014
    Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014
    Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting
    Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial
    Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing's Syndrome
    Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing's Syndrome
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Amryt Pharma plc, H1 2017
    Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
    Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
    Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Ipsen SA, H1 2017
    Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Millendo Therapeutics Inc, H1 2017
    Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Novartis AG, H1 2017
    Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Pfizer Inc, H1 2017
    Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, H1 2017
    Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, H1 2017
    Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Amryt Pharma plc
    Crinetics Pharmaceuticals Inc
    Cyclacel Pharmaceuticals Inc
    Ipsen SA
    Millendo Therapeutics Inc
    Novartis AG
    Pfizer Inc
    Strongbridge Biopharma plc

    Request for Sample

    Report Url http://www.reportsweb.com//pituitary-acth-hypersecretion-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//pituitary-acth-hypersecretion-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//pituitary-acth-hypersecretion-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments